• Medicine, Health Systems and Governance, Pharmacovigilance

Research Interests

  • Medicine Sciences and Health Systems, Toxicology, Regulatory Disciplines
Back to Adjunct Faculty

Kenneth Y. Hartigan-Go, MD, MD (UK)

Adjunct Faculty

Academic Background

  • Doctor of Medicine, College of Medicine, University of the Philippines-Manila
  • Doctor of Medicine, University of Newcastle-upon-Tyne (UK)
  • Bachelor of Science, College of Arts and Sciences, University of the Philippines Diliman
  • Diplomate and Fellow, Internal Medicine, Philippine College of Physicians

Professional and Academic Experience

Corporate Positions

  • Independent Director, Equicom Savings Bank Board (2010- present)
  • Independent Director, Maxicare Corporation Board (2016-present)

Faculty Positions

  • Head, Stephen Zuellig Graduate School of Development Management, Asian Institute of Management (December 2016 – 2020)
  • Academic Director, Stephen Zuellig Graduate School for Development Management, Asian Institute of Management (December 2014 – May 2015)
  • Faculty, Asian Institute of Management and Executive Director of Dr. Stephen Zuellig Center for Asian Business Transformation (Sept 1, 2010 – Sept 30, 2012) 
  • Adjunct Faculty, Center for Development, Management Asian Institute of Management (June 1 – August 2010)
  • Visiting Faculty, Ateneo School of Medicine and Public Health (2007–2010)   
  • Assistant Professor until Professor III, Department of Pharmacology and Toxicology, University of the Philippines College of Medicine (1990 – 2005 )   
  • Clinical Associate Professor, Department of Internal Medicine, Philippine General Hospital (1991-1992)   

Hospital Positions

  • Certified internist at three private hospitals responsible for managing cases of substance abuse and consulting on treatment of illnesses related to toxic substances (1992 – 2012)
  • Consultant, National Poison Control and Information Service for Philippine General Hospital (1990–2005)

Special National/Local Responsibilities

  • Undersecretary for Health Regulation, Department of Health (appointed: 15 May 2015, ended 11 July 2016)
  • Chair, Research committee (formerly Secretary 2008-2009), Medicine Transparency Alliance Council of the Philippines (MeTA) (a project funded by UK);
  • Consultant to the Senate Committee on Health and Demographics (since 2011); 
  • Regent, the Philippine College of Physicians (PCP) (since 2008);
  • Member of the UP Universal Health Care group of UP;   
  • Member of the Health Technology Assessment (HTA) Committee of the government’s National Health Insurance Program within the Philippine Health Insurance Corporation (PHIC), evaluating health technology and products, and advocating evidenced-based sound policy in the areas of financing, drug and medical procedure reimbursement; 
  • Coordinator for Secretary of Health, APEC Life Science Innovation Forum (September 2013-June 2016)
  • Member, Bioethics Advisory Committee for Stem Cell Concerns (2014-2016)
  • Elected as new board member, Asia Pacific Association of Medical Toxicologist (APAMT); Vice-Chair, National Quality Infrastructure  (under National Competitiveness Council); Member, Steering Committee of NUS Initiative to Promote Health in Asia (NIHA)
  • Member, WHO HQ Advisory Committee on the Safety of  Medicinal Products (2001-2014, renewed 2016)
  • Director IV, Department of Health-Food and Drug Administration; Health Scientist to National Committee of Biosafety of the Philippines (2010-2014) (DOST)
  • President, International Society For Pharmacoeconomics and Outcomes Research  (ISPOR), Philippines (2012 - 2014; re-elected 2017)
  • Member, Formulary Executive Council (2012 - 2013)
  • President of the Philippine Society of Experimental and Clinical Pharmacology (2010 - 2011)
  • Convenor of the first Health Finance Summit co-organized the University 0f the Philippines, De La Salle University, Ateneo de Manila University and the Asian Institute of Management (April 2010)
  • Consultant to the EU- FP7 (Framework Project) Monitoring of Medicines work plan 1- 4 (Jan 2010–2013)   
  • Consultant to the Chairman of the Committee on Health in the Philippine House of Representatives (2008 - 2009)
  • Board of Trustees, the League of Corporate Foundations (LCF) (2007 - 2008)
  • Member, WHO HQ Global Advisory Committee on Vaccine Safety (2006 - 2012)
  • President, the Corporate Network for Disaster Response (CNDR) (2005 - 2009)
  • Two - 3 year terms as Member of the Executive Committee of the International Society of Pharmacovigilance (ISoP) and Vice President on the last term (2004– 2009 )  
  • Resource Expert on Pharmaceutical Regulatory Science Network in APEC meetings (2004)
  • Former Member, Health Panel, Congressional Commission on Science, Technology and Engineering (2002-2008)
  • Founding Executive Director, Zuellig Family Foundation (June 1, 2001–Dec 30, 2009) 
  • Member of technical committee, briefly served as Vice Chair of the Dangerous Drugs Board (2001)
  • Deputy Director, Bureau of Food and Drugs in Philippine Department of Health and, concurrently, Manager, National Drug Policy Program in Philippine Department of Health. In collaboration with Secretary of Health, crafted health sector reform agenda that created FOURmula One for Health that in 2005 became the guiding implementation framework for health sector reforms. (1999-2001)  
  • Member of the investigating team, examination of Filipinos in Taiwan who suffered from a mystery disease, in collaboration with the 
    Department of Health, the Department of Labor and Employment and Taiwanese authorities (1996–1999)
  • Founder, Adverse Drug Reaction Monitoring Program for the Philippine Government in partnership with Australian Assistance for International Development.  Served as Project Leader, Adverse Drug Reaction Monitoring Programme  and Vice-Chairman, National Adverse Drug Reaction Advisory Committee (DOH-NDP-AusAID Cooperation) (1994 - 2007)
  • Founding Member and Country Director, Association of Medical Doctors for Asia.  Created and organized local slum clinic at which health services provided at minimal cost to indigent families.  Arranged for  drug donations from private pharmaceutical firms and provided public  health education in addition to treatment.  Clinic services eventually  assumed by local NGO.  Also provided community disaster preparedness services and advice. (1990-1992 and 1994-1999)


  • Consultant to the following USAID projects: Private Sector Mobilization for Family Planning (PRISM): Assessed Contraceptive Self-Reliance response in private sector and identified interventions to address problems; provided expert advice on product registration of hormonal products and at various Technical Working Groups Meetings and Midwives’ Congress aimed to enhance the midwives’ roles in light of the domestic and global developments in human resources for health. 
  • TBLinc: evaluated private sector provider behaviors and made recommendations on how they could be engaged to promote TB DOTS, linking drug stores as DOTS centers with the DOH DOTS program.
  • Health Policies Development Program (HPDP):  (1) Assessed contraceptive self-reliance response in the private sector.  Identified and clarified roles of the various private sector stakeholders that need to be developed through a system of investments that includes incentives and regulatory policies. Assessed and evaluated current contributions of the different private stakeholders in adding value to national FP programs.  (2) Assessed knowledge base of local chief executives in apply financing or securing a budget to ensure contraceptive self-reliance and coverage for unmet needs of women in their reproductive age in the poorer sector of society, how to apply for support from the national government and donors, and to work with the private sector.  Assessed role of government in supporting private sector entry and participation.
  • Public-Private Sector Partnership Consultancy Project: assisted the Philippine Government to gain private and business sector support for strengthening the national avian flu preparedness plan and the flu pandemic preparedness and response plan.
  • Consultant, Formulation Mission, Health Sector Policy Support Programme, European Commission.  Participated in the preparation of the health sector reform agenda, focusing specifically on the roles and requirements of local government units. Assignment involved interface with the provincial governors and their administration, interviews and research in the field and conducting workshops with health personnel of the province. (2005)
  • Short-term Consultant and Adviser to the World Health Organization on drug regulation, pharmacovigilance, and medical toxicology. Currently, sits in two Global WHO Committees.(1989–Present)   

Affiliations, Awards, and Honors

  • Fellow of the American College of Physicians
  • Fellow of the Royal College of Physicians (Edinburgh)
  • Fellow, Institute of Corporate Directors
  • UP Reserve Officers Training Corp program: Honor Sword, two Honor Star medals, Leadership medal (1978-1981)
  • Philippine Board Certified Internist, Philippine College of Physicians, 1992
  • Medicine, Board of Medicine, Professional Regulation Commission, 1986
  • The Drug Information Association Outstanding Service Award, USA (2001)
  • Distinguished Fellow Award from the Philippine College of Physicians (2008)
  • Recipient of Dr. Jose P. Rizal Award for Excellence as Outstanding Chinese Filipino in the field of Medicine, The Manila Times (2008)
  • Outstanding Graduate Award, ROTC, Armed Forces of the Philippines (2012)


  • Bate, A., Beckmann, J., Dodoo, A., Härmark, L., Hartigan-Go, K., Hegerius, A., . . . Hagemann, U. (2017). Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery. Drug Safety, 40(3), 191-199. doi:10.1007/s40264-016-0495-9
  • Edwin J. Asturias, Melinda Wharton, Robert Pless, Noni E. MacDonald, Robert T. Chen, Nicholas Andrew, David Salisbury, Alexander N. Dodoo, Kenneth Hartigan-Go, Patrick L.F. Zuber. “Contributions and challenges for worldwide vaccine safety: The Global Advisory Committee on Vaccine Safety at 15 years”. Vaccine 34 (2016), pp. 3342-3349
  • Beckmann J, Hartigan-Go K, “Teaching Pharmacovigilance: the WHO-ISop Core Elements of a Comprehensive Modular 37: 743-759 Drug Safety

This website uses information-gathering tools, such as cookies, web analytics, and other similar technology. By using this website, you consent to the use of these tools.

View Privacy Policy